Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 125.9% in December

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 6,100 shares, an increase of 125.9% from the November 30th total of 2,700 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average trading volume of 9,000 shares, the short-interest ratio is presently 0.7 days.

Armata Pharmaceuticals Price Performance

Shares of Armata Pharmaceuticals stock opened at $2.02 on Friday. Armata Pharmaceuticals has a one year low of $1.85 and a one year high of $4.48. The company has a market capitalization of $73.08 million, a PE ratio of -1.23 and a beta of 0.78.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.